PGNY
Progyny, Inc.
Healthcare · Medical - Healthcare Information Services
Undervalued·Quality 70·RSI 28·DCF +41%·Conviction 75
Investment Thesis — Progyny, Inc.
The market overstates Progyny's margin compression and underappreciates the stickiness of its employer relationships, mispricing the durability of its growth and pricing power. Investors extrapolate recent margin headwinds as structural, missing the company's ability to reprice contracts and expand services within existing clients.
Catalysts
- Contract repricing with major employer clients
- Expansion of services or new product launches
- Easing cost pressures improving gross margin
Risk Factors
- Sustained cost inflation compressing margins
- Loss of key employer clients
- Delayed or failed product expansion
Key Debates
Fwd Revenue Growth Exceeds 10% by Q4, Re-rating P/E to 20x
Strong Q3 Earnings Trigger Short Squeeze, Pushing Price Past $25 by Q4
PGNY Achieves Analyst PT of $30.80 by Q1 2025 on Sustained Growth